Show simple item record

dc.contributor.authorConrado, Daniela J
dc.contributor.authorNicholas, Timothy
dc.contributor.authorTsai, Kuenhi
dc.contributor.authorMacha, Sreeraj
dc.contributor.authorSinha, Vikram
dc.contributor.authorStone, Julie
dc.contributor.authorCorrigan, Brian
dc.contributor.authorBani, Massimo
dc.contributor.authorMuglia, Pierandrea
dc.contributor.authorWatson, Ian A
dc.contributor.authorKern, Volker D
dc.contributor.authorSheveleva, Elena
dc.contributor.authorMarek, Kenneth
dc.contributor.authorStephenson, Diane T
dc.contributor.authorRomero, Klaus
dc.date.accessioned2018-02-15T23:23:50Z
dc.date.available2018-02-15T23:23:50Z
dc.date.issued2018-01
dc.identifier.citationDopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis. 2018, 11 (1):63-70 Clin Transl Scien
dc.identifier.issn1752-8062
dc.identifier.pmid28749580
dc.identifier.doi10.1111/cts.12492
dc.identifier.urihttp://hdl.handle.net/10150/626602
dc.description.abstractGiven the recognition that disease-modifying therapies should focus on earlier Parkinson's disease stages, trial enrollment based purely on clinical criteria poses significant challenges. The goal herein was to determine the utility of dopamine transporter neuroimaging as an enrichment biomarker in early motor Parkinson's disease clinical trials. Patient-level longitudinal data of 672 subjects with early-stage Parkinson's disease in the Parkinson's Progression Markers Initiative (PPMI) observational study and the Parkinson Research Examination of CEP-1347 Trial (PRECEPT) clinical trial were utilized in a linear mixed-effects model analysis. The rate of worsening in the motor scores between subjects with or without a scan without evidence of dopamine transporter deficit was different both statistically and clinically. The average difference in the change from baseline of motor scores at 24 months between biomarker statuses was -3.16 (90% confidence interval [CI] = -0.96 to -5.42) points. Dopamine transporter imaging could identify subjects with a steeper worsening of the motor scores, allowing trial enrichment and 24% reduction of sample size.
dc.description.sponsorshipParkinson's United Kingdom; AbbVie; Biogen; Eli Lilly; GE Healthcare; Lundbeck; Merck Sharp and Dohme; Pfizer; UCB; Michael J. Fox Foundation; Avid; Bristol-Myers Squibb; Convance; Genentech; GSK; Lilly; Merck; Meso Scale Discovery; Pfizer, Piramal; Roche; Sanofi Genzyme; Servier; TEVA; Golub Capitalen
dc.language.isoenen
dc.publisherWILEYen
dc.relation.urlhttp://onlinelibrary.wiley.com/doi/10.1111/cts.12492/abstract;jsessionid=D62C7AF32F41812F5EB354E06526867A.f02t04en
dc.rights©2017 ASCPT. All rights reserved. Published 2017. This article is a U.S. Government work and is in the public domain in the USA. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution License.en
dc.titleDopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis.en
dc.typeArticleen
dc.contributor.departmentUniv Arizonaen
dc.identifier.journalClinical and translational scienceen
dc.description.noteOpen access journal.en
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en
dc.eprint.versionFinal published versionen
refterms.dateFOA2018-07-01T04:36:29Z
html.description.abstractGiven the recognition that disease-modifying therapies should focus on earlier Parkinson's disease stages, trial enrollment based purely on clinical criteria poses significant challenges. The goal herein was to determine the utility of dopamine transporter neuroimaging as an enrichment biomarker in early motor Parkinson's disease clinical trials. Patient-level longitudinal data of 672 subjects with early-stage Parkinson's disease in the Parkinson's Progression Markers Initiative (PPMI) observational study and the Parkinson Research Examination of CEP-1347 Trial (PRECEPT) clinical trial were utilized in a linear mixed-effects model analysis. The rate of worsening in the motor scores between subjects with or without a scan without evidence of dopamine transporter deficit was different both statistically and clinically. The average difference in the change from baseline of motor scores at 24 months between biomarker statuses was -3.16 (90% confidence interval [CI] = -0.96 to -5.42) points. Dopamine transporter imaging could identify subjects with a steeper worsening of the motor scores, allowing trial enrichment and 24% reduction of sample size.


Files in this item

Thumbnail
Name:
Conrado_et_al-2018-Clinical_an ...
Size:
743.7Kb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record